Pacific Biosciences of California, Inc. Overview
Pro stress-test →Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company develops instrument systems and software for real-time sequencing of single-molecules. PacBio's technology enables comprehensive analysis of genomes, transcriptomes, and epigenomes across clinical, research, and agricultural applications.
Strategic Profile
Pro stress-test →The company reported Q1 2026 revenue of $37.2 million (flat year-over-year) with consumable revenue of $21.8 million offsetting weaker instrument sales. GAAP gross margin improved to 35% from negative 4% a year ago, and GAAP net loss narrowed sharply to $8.3 million from $426.1 million. In February 2026, PacBio completed the sale of select short-read DNA sequencing assets to Illumina for $48.1 million in net cash proceeds, allowing the company to focus exclusively on long-read sequencing.
Competitive Landscape
Pro stress-test →Pacific Biosciences competes with Complete Genomics, Twist Bioscience, 10x Genomics, and Singulex in genomic sequencing and analysis. PacBio's long-read SMRT technology differentiates it from short-read competitors like Illumina, positioning it in a specialized market segment with growing clinical and research adoption.
Industry Context
Pacific Biosciences of California, Inc. operates in Genomic Sequencing and Analysis.
Key facts
Founded: 2004 · Headquarters: Menlo Park, California · Employees: N/A · Revenue: $37.2M (Q1 2026) · Market cap: N/A